Canify AG and Africa’s first EU-GMP certified producer of medical cannabis flowers and extracts, MG Health Limited, have announced their planned merger. In a signed Memorandum of Understanding (MoU), the two companies have agreed to expand their successful two-year partnership into a joint holding structure. The group will be a fully vertically integrated medical cannabis platform, encompassing EU GMP certified production, pharmaceutical processing and multi-market distribution, with a commercial presence in more than 7 countries including Germany, UK, Australia and Poland, as well as a unique global supplier network.

The two companies have worked closely together since Q4 2024, when MG Health began supplying Canify with medical cannabis flower on an ongoing basis. This proven supply relationship now forms the operational basis for a full merger. “Mutual trust has grown from our good working relationship, so it is only logical to take our cooperation to the next level,” says Sascha Mielcar, CEO of Canify AG. “In addition to quality standards, we also share a common attitude: patients are at the center of everything we do. Our shared vision is to create a globally active pharmaceutical company with a clear focus on the highest quality standards and clinical innovation.”

The proposed merger will create a vertically integrated structure that is unique in the European medical cannabis market. The combined team will control all critical steps of the pharmaceutical value chain: from EU GMP certified flower cultivation and extraction at MG Health’s Lesotho facility, management of pharmaceutical processing regulations, and multi-channel distribution through Canify’s established network of pharmaceutical partnerships and its direct-to-patient Canify Clinics platform.

MG Health’s production platform provides the combined group with a significant structural cost advantage. Operating at an altitude of 2,000 meters in Lesotho’s Maluti Mountains, the facility has ideal growing conditions, low energy costs and year-round natural light, enabling pharmaceutical-grade production at a fraction of the cost of facilities in Europe. Beyond operational efficiency, MG Health has invested significantly in the local community, creating hundreds of sustainable jobs, expanding local infrastructure and providing education and development programs for employees, their families and surrounding communities.

“As a company that puts people first, we do not see financial success as an end in itself, but as a means to enable positive and lasting change in our society,” says Andre Bothma, CEO of MG Health. “This principle shapes our daily actions in Lesotho: from responsible, sustainable management and long-term employment opportunities to targeted educational initiatives. In Canify, we have found a partner who shares these values ​​and will carry them forward with us.”

“The merger allows us to align our processes with expertise and regulatory frameworks throughout the value chain, and therefore complement each other seamlessly,” explains Mielcarek. For example, Canify’s international supplier network can be perfectly aligned with MG Health’s expanded production and processing capabilities. “At the same time, with MG Health, we are strengthening our approach that combines pharmaceutical excellence, social responsibility and environmental sustainability.”

For more information:
Canify AG
https://canify.com/

MG Health Limited
mghealth.com/

“There’s a part of me where my heart is dancing because we’re so much closer. So right now there’s more gratitude than anything.”

By Anna Barrett, Alabama Reflector

Callie’s Apothecary’s Montgomery location doesn’t look like much.

But standing on concrete floors and surrounded by metal beams, owner Vince Schilleci described what the “next to the pharmacy” storefront will look like.

And when Callie’s opens, which Schilleci believes could happen in April, it will likely be the first place to buy medicinal cannabis in Alabama.

“We’ll have someone come and check, scan the card to make sure you’re a real patient recommended for medicinal cannabis,” he said. “For privacy, you have to wait outside here until you get to the sales floor. Our goal is to get people in and out as quickly as possible, because it’s a safety issue. We don’t want people walking around.”

The opening could be a landmark, nearly five years after the Legislature passed a law authorizing medicinal cannabis, and after years of litigation and frustrating licensing processes.

Amanda Taylor, a medical cannabis patient advocate, has been part of the commission’s process since 2021. He has multiple sclerosis with 45 lesions in his brain and one in his spine. He welcomes the opening, but said in an interview Thursday that the delay caused it.

“There’s a part of me where my heart is dancing because we’re so much closer. So there’s more gratitude than anything right now,” Taylor said. “The suffering that the patients had to endure because of the lawsuits, the suffocating suffering, he took that away from the patients.”

licenses

The Alabama Medical Cannabis Commission (AMCC) has issued three dispensary licenses, and Schilleci’s shop, doing business as Alabama CCS, is expected to be the first to open, according to AMCC General Counsel Justin Aday.

“I don’t think anyone is dragging their feet. There are a lot of balls in the air with different stakeholders working,” Aday said.

CCS; GP6 Wellness, Birmingham, and Montgomery-based RJK Holdings received the licenses in December. A fourth dispensary license has yet to be awarded, but it is likely to go to Yellowhammer dispensaries, according to Aday. The commission delayed issuing Yellowhammer’s license in December because of the lawsuit, but Aday said the commission asked for a quick decision, which he hopes will be resolved soon. Once done, there will be 12 dispensaries in the state.

Schilleci said two more Callie’s Apothecary locations will be opening in a few months: one in Talladega, and one in Bessemer, following a last-minute location change in Cullman.

Schilleci said in an interview last month that the company was able to take more business risks because it did not challenge the licensing process.

“We invested in a lot of equipment, with the license in hand, instead of applying for them, we would be ready to go,” Schilleci said. “Before we had the license in hand, we gambled a bit by spending money, but things felt good.”

A pharmacy is not a pharmacy, so the staff there will not be able to give medical advice, said Schilleci. But the dispensary will have a consultation room if patients have questions about products recommended by board-certified doctors, a prerequisite for obtaining medicinal cannabis.

As of last Friday, there were 20 doctors in Alabama certified to recommend medical cannabis to patients, according to the Alabama Board of Medical Examiners. Aday said in an interview Wednesday that about nine of the certified doctors were registered through the commission’s patient registry.

“I think it would be strange to go through the process with the board of medical examiners not to use that certification,” Aday said.

Doctors will not prescribe medicinal cannabis. Instead, they will recommend a product they believe will work for a patient with a qualifying condition, including cancer, depression, Parkinson’s disease, post-traumatic stress disorder (PTSD), sickle cell anemia, chronic pain, and terminal illness.

Acceptable product forms are limited to tablets, tinctures, patches, oils, and gummies (peach flavor only), herbal raw materials and smoking forms are prohibited.

Each qualifying patient must register with the board to receive a doctor’s recommendation and receive a cannabis product from a dispensary.

“We want to make sure that we’re not only going to be professional and serve our clients, but we’re also going to be compassionate because they’re people with serious illnesses,” Schilleci said. “This is not a retail business. Yes, it’s retail, but it’s something more. At the end of the day it’s a call to serve.”

Lawsuits have hindered access to medical cannabis. Some companies sued the commission for not issuing licenses, citing a discriminatory process. In another case five parents sued the board over delays in accessing cannabis, which was dismissed in August.

Who will participate?

As of last Friday, fewer than 10 patients had signed up for medical cannabis, and Aday said it’s difficult to estimate how many patients will benefit from the program.

Schilleci knew the process of getting the product into patients’ hands would take some time, but she said she was grateful to be done soon.

“For patients, they’ve been waiting too long, it’s time to get this product to them,” Schilleci said. “I can’t get over it. It’s amazing how many people are already calling saying, ‘Hey, when are you opening? We’re ready for this.'”

Taylor said in an interview that she has received more than 700 emails from Alabamians through her work as a patient advocate, but patients will also contact her through texts, phone calls and social media.

“It can be overwhelming, but at the same time there are days with my illness where I can’t really walk much, so I can dedicate my time because I can’t do anything else,” he said.

Even though he’s nearing the end of his nearly five-year journey to medical cannabis, Taylor said it’s been exhausting.

“I mean no matter how you look at it, it’s a win for patients,” he said. “I can’t wait to celebrate for patients.”

Dispensary locations:

CCS of Alabama, LLC

• • Montgomery, Bessemer and Talladega

GP6 Wellness, LLC

• • Birmingham, Athens and Attalla

RJK Holdings, LLC

• • Oxford, Daphne and Mobile

Yellowhammer Medical Dispensary, LLC *pending license approval

• • Birmingham, Owens Cross Roads and Demopolis

This story was first published by the Alabama Reflector.

In early March 2026, experts from industry, technology, finance and academia from around the world gathered in London for the inaugural Biochar Commercialization Summit. The aim of this first conference was to find ways to expand the production and application of biochar throughout the world.

Dr. Sebastian Kipp represented Klasmann-Deilmann at the event and participated in the opening panel discussion on the conditions companies must meet to use biochar on a larger scale.

Biochar as a sustainable carbon sequestration component
Biochar is considered a promising technology for permanent carbon sequestration. While many climate strategies focus on reducing emissions, biochar can remove CO₂ from the atmosphere in the long term.

However, scaling up this technology is complex. The value chain involves many actors, including biochar producers, energy companies, project promoters and buyers of CO₂ certificates.

The crucial factor is to ensure that the biochar actually ends up in a sustainable carbon sink. CO₂ certificates can only be created and traded when this condition is met.

© Klasmann-Deilmann

Horticulture as a previously underestimated player
Biochar is mainly considered in the context of agriculture in many discussions. Professional horticulture has played a much smaller role in the perception of the industry until now. This is precisely what Klasmann-Deilmann brought to the summit with a new perspective.

“We are one of the few companies that can use biochar functionally, that is, as a component of growth media,” explains Sebastian Kipp. “Through our value chain, the biochar eventually ends up in the soil, where it is bound for the long term.”

High interest among potential customers
The perspective of an industrial user was met with great interest by the participants of the summit. “After explaining the quantities that could theoretically be used by root, there was a lot of interest,” reports Sebastian Kipp. Numerous discussions with producers and project developers revealed that reliable contractors are essential for the establishment of new production capacities.

Raw materials and global supply chains
Another main topic of the conference was the identification of suitable biogenic raw materials for biochar production. Although wood chips are commonly used today, they are quite expensive.

As a result, the discussion about the use of biogenic waste, which has not been widely used until now, has increased. Large quantities of this type of biomass are available, especially in regions such as Africa and India. Greater use of these resources can reduce production costs in the long term and facilitate the development of new international production structures.

Options for use in growth media
Klasmann-Deilmann is working to further expand the use of biochar in growth media. Trials are currently underway using larger amounts of TerraCoal in young plant growth media. At the same time, the supplier network is being expanded, wherever possible, to establish stable regional supply chains in the long term.

The discussions in London revealed that gardening can play an important role in the future biochar value chain. Their use in growth media establishes a link between biochar production and agricultural application, providing a complementary method of long-term carbon sequestration.

For more information:
Klasmann-Deilmann Benelux
(email protected)
www.klasmann-deilmann.com